Bristol-Myers Squibb (BMY) Tops Q3 EPS by 17c, Beats on Revenue, Offers FY22 Revenue Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $63.06 +0.35%
Revenue Growth %: +3.2%
Financial Fact:
Net Earnings: 1.22B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +3.2%
Financial Fact:
Net Earnings: 1.22B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.99, $0.17 better than the analyst estimate of $1.82. Revenue for the quarter came in at $11.22 billion versus the consensus estimate of $11.15 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 revenue of $46 billion, versus the consensus of $46 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Raised to $82 at Piper Sandler
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
